Alberto Papi

48.7k total citations · 14 hit papers
501 papers, 22.7k citations indexed

About

Alberto Papi is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Immunology. According to data from OpenAlex, Alberto Papi has authored 501 papers receiving a total of 22.7k indexed citations (citations by other indexed papers that have themselves been cited), including 340 papers in Pulmonary and Respiratory Medicine, 294 papers in Physiology and 69 papers in Immunology. Recurrent topics in Alberto Papi's work include Asthma and respiratory diseases (291 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (218 papers) and Respiratory and Cough-Related Research (125 papers). Alberto Papi is often cited by papers focused on Asthma and respiratory diseases (291 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (218 papers) and Respiratory and Cough-Related Research (125 papers). Alberto Papi collaborates with scholars based in Italy, United Kingdom and United States. Alberto Papi's co-authors include Leonardo M. Fabbri, Sebastian L. Johnston, Gaetano Caramori, Marco Contoli, Helen K. Reddel, Christopher E. Brightling, Søren Pedersen, Paolo Casolari, Dave Singh and Marina Saetta and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Alberto Papi

464 papers receiving 22.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Asthma

2017 1.2k citations Alberto Papi, Christopher E. Brightling et al. profile →
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

2016 976 citations Alberto Papi et al. profile →
Infections and Airway Inflammation in Chronic Obstructive Pulmonary Disease Severe Exacerbations

2006 781 citations Alberto Papi, Cinzia Maria Bellettato et al. American Journal of Respiratory and Critical Care Medicine profile →
Role of deficient type III interferon-λ production in asthma exacerbations

2006 777 citations Marco Contoli, Simon Message et al. profile →
Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease

2020 463 citations Gerard J. Criner, Alberto Papi et al. American Journal of Respiratory and Critical Care Medicine profile →
Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline

2017 452 citations Gerard J. Criner, Alberto Papi et al. European Respiratory Journal profile →
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults

2023 405 citations Alberto Papi et al. profile →
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial

2018 398 citations Alberto Papi, Leonardo M. Fabbri et al. profile →
Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma

2019 266 citations Richard Beasley, Alberto Papi et al. profile →
Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for Its Revision

2022 244 citations Bartolomé R. Celli, Leonardo M. Fabbri et al. American Journal of Respiratory and Critical Care Medicine profile →
Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact

2021 158 citations Alberto Papi, Marco Contoli et al. profile →
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation

2024 102 citations Surya P. Bhatt, Klaus F. Rabe et al. profile →
Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype

2025 22 citations Gerard J. Criner, Alberto Papi et al. profile →
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials

2025 18 citations Surya P. Bhatt, Klaus F. Rabe et al. The Lancet Respiratory Medicine profile →

Peers

Countries citing papers authored by Alberto Papi

Since Specialization

Citations

This map shows the geographic impact of Alberto Papi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alberto Papi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alberto Papi more than expected).

Fields of papers citing papers by Alberto Papi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alberto Papi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alberto Papi. The network helps show where Alberto Papi may publish in the future.

Co-authorship network of co-authors of Alberto Papi

This figure shows the co-authorship network connecting the top 25 collaborators of Alberto Papi. A scholar is included among the top collaborators of Alberto Papi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alberto Papi. Alberto Papi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The ROME COPD exacerbation proposal works! Time to move forward 2025 ·American Journal of Respiratory and Critical Care Medicine ·Bartolomé R. Celli, Leonardo M. Fabbri, Gerard J. Criner, Alberto Papi, Antoni Torres, Àlvar Agustí	0
2	Effect of dupilumab on mucus burden in patients with moderate-to-severe asthma: the VESTIGE trial 2025 ·American Journal of Respiratory and Critical Care Medicine ·Celeste Porsbjerg, Eleanor M. Dunican, Njira Lugogo, Mario Castro, Alberto Papi, Vibeke Backer, Christopher E. Brightling, (unknown), J. Christian Virchow, Mei Zhang, Xavier Soler, Paul J. Rowe, Yamo Deniz, (unknown), Harry Sacks, Juby A. Jacob‐Nara	0
3	Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial 2025 ·The Lancet Respiratory Medicine ·Stephanie A. Christenson, Nicola A. Hanania, Surya P. Bhatt, Mona Bafadhel, Klaus F. Rabe, Claus Vogelmeier, Alberto Papi, (unknown), Elizabeth Laws, Paula Dakin, Ashish Bansal, Xin Lu, (unknown), Jennifer Maloney, Lacey B. Robinson, Raolat M. Abdulai	5
4	Dupilumab Improves Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUS 2025 ·CHEST Journal ·Surya P. Bhatt, Klaus F. Rabe, Nicola A. Hanania, Claus Vogelmeier, Mona Bafadhel, (unknown), Alberto Papi, Dave Singh, Elizabeth Laws, Paula Dakin, Jennifer Maloney, Xin Lu, (unknown), Ashish Bansal, Raolat M. Abdulai, Lacey B. Robinson	1
5	Albuterol-budesonide rescue reduces progression from asthma deterioration to severe exacerbation 2024 ·The Journal of Allergy and Clinical Immunology In Practice ·(unknown), Alberto Papi, Richard Beasley, Elliot Israel, Reynold A. Panettieri, Frank C. Albers, Mark E. Cooper, (unknown), Ileen Gilbert, Frank Trudo, Mark Weinberg, (unknown)	0
6	Dupilumab Improves Pre-bronchodilator Lung Function Measures in Patients With Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation: Data From the Phase 3 Boreas Trial 2024 ·Alberto Papi, Nicola A. Hanania, Surya P. Bhatt, Klaus F. Rabe, Claus Vogelmeier, Mona Bafadhel, Stephanie A. Christenson, Dave Singh, Elizabeth Laws, (unknown), Ashish Bansal, (unknown), Dirk Bauer, Jennifer Maloney, Lacey B. Robinson, Raolat M. Abdulai	1
7	A Long-Term Study of Adverse Outcomes Associated With Oral Corticosteroid Use in COPD 2023 ·International Journal of COPD ·Gary Tse, Benjamin Emmanuel, Cono Ariti, Mona Bafadhel, Alberto Papi, Victoria Carter, Jiandong Zhou, Derek Skinner, Xiao Xu, Hana Müllerová, David Price	12
8	Development of a tool to detect small airways dysfunction in asthma clinical practice 2022 ·European Respiratory Journal ·Janwillem Kocks, Thys van der Molen, Jaco Voorham, S. Baldi, Maarten van den Berge, Christopher E. Brightling, Leonardo M. Fabbri, Monica Kraft, Gabriele Nicolini, Alberto Papi, Klaus F. Rabe, Salman Siddiqui, Dave Singh, Judith M. Vonk, (unknown), Bertine M.J. Flokstra-de Blok	7
9	Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction 2022 ·Annals of Allergy Asthma & Immunology ·Nicola A. Hanania, Mario Castro, Eric D. Bateman, Ian Pavord, Alberto Papi, J. Mark FitzGerald, Jorge Máspero, Constance H. Katelaris, Dave Singh, Nadia Daizadeh, Arman Altincatal, (unknown), Xavier Soler, Shahid Siddiqui, Elizabeth Laws, Juby A. Jacob‐Nara, Paul J. Rowe, David J. Lederer, Megan Hardin, Yamo Deniz	8
10	Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies 2021 ·Therapeutic Advances in Respiratory Disease ·Giorgio Walter Canonica, Pierluigi Paggiaro, Francesco Blasi, Antonino Musarra, Luca Richeldi, Andrea Rossi, Alberto Papi	10
11	CAPTAIN STUDY: EFFECT OF BASELINE LUNG FUNCTION ON RESPONSE TO TRIPLE THERAPY IN PATIENTS WITH ASTHMA INADEQUATELY CONTROLLED ON INHALED CORTICOSTEROID/LONG-ACTING BETA2-AGONIST THERAPY 2020 ·CHEST Journal ·Robert A. Nathan, Louis‐Philippe Boulet, Huib A.M. Kerstjens, Alberto Papi, Ian Pavord, Nicola A. Hanania, John Oppenheimer, (unknown), Mark Liu, Steven P. Weinstein, David M. Mannino, Guy Peachey, (unknown), Neal Sule, Andrew Fowler, (unknown), Edward Kerwin	0
12	The efficacy of extrafine beclomethasone dipropionate–formoterol fumarate in COPD patients who are not "frequent exacerbators": a post hoc analysis of the FORWARD study 2017 ·International Journal of COPD ·Dave Singh, Stefano Vezzoli, Stefano Petruzzelli, Alberto Papi	3
13	Th2 cytokines impair innate immune responses to rhinovirus in respiratory epithelial cells 2015 ·Allergy ·Marco Contoli, Kazuhiro Ito, Anna Padovani, (unknown), Brunilda Marku, Michael R. Edwards, L Stanciu, Giulia Gnesini, (unknown), Antonio Spanevello, Paolo Morelli, Sebastian L. Johnston, Gaetano Caramori, Alberto Papi	129
14	Fluticasone propionate/formoterol fumarate improves asthma control and reduces exacerbations compared with fluticasone 2013 ·European Respiratory Journal ·Alberto Papi, David Price, J. Sastre, (unknown), Mark Lomax, Tammy McIver, Sanjeeva Dissanayake	2
15	Rhinovirus infection causes steroid resistance in airway epithelium through nuclear factor κB and c-Jun N-terminal kinase activation 2013 ·Journal of Allergy and Clinical Immunology ·Alberto Papi, Marco Contoli, Ian M. Adcock, Cinzia Maria Bellettato, Anna Padovani, Paolo Casolari, L Stanciu, Peter J. Barnes, Sebastian L. Johnston, Kazuhiro Ito, Gaetano Caramori	73
16	“Interferon-γrelease assays for the diagnosis of latentMycobacterium tuberculosisinfection: a systematic review and meta-analysis.” R. Diel, D. Goletti, G. Ferrara, G. Bothamley, D. Cirillo, B. Kampmann, C. Lange, M. Losi, R. Markova, G.B. Migliori, A. Nienhaus, M. Ruhwald, D. Wagner, J.P. Zellweger, E. Huitric, A. Sandgren and D. Manissero.Eur Respir J2011; 37: 88–99. 2012 ·European Respiratory Journal ·Christopher A. Hewson, Jürgen Haas, Nathan W. Bartlett, Simon Message, Vasile Laza‐Stanca, Tatiana Kebadze, Gaetano Caramori, (unknown), Mark R. Edbrooke, (unknown), Onn Min Kon, Alberto Papi, Peter Jeffery, Matthew Edwards	11
17	“Interferon-γrelease assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis.” M. Sester, G. Sotgiu, C. Lange, C. Giehl, E. Girardi, G.B. Migliori, A. Bossink, K. Dheda, R. Diel, J. Dominguez, M. Lipman, J. Nemeth, P. Ravn, S. Winkler, E. Huitric, A. Sandgren and D. Manissero.Eur Respir J2011; 37: 100–111. 2012 ·European Respiratory Journal ·Christopher A. Hewson, (unknown), Nathan W. Bartlett, Simon Message, Vasile Laza‐Stanca, Tatiana Kebadze, Gaetano Caramori, (unknown), Mark R. Edbrooke, L Stanciu, Onn Min Kon, Alberto Papi, Peter Jeffery, Matthew Edwards	15
18	Ruolo delle cellule staminali nella patogenesi della broncopneumopatia cronica ostruttiva e dell’enfisema polmonare 2012 ·Recenti Progressi in Medicina ·Gaetano Caramori, Paolo Casolari, (unknown), (unknown), (unknown), Marco Contoli, Alberto Papi	10
19	Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production 2008 ·Proceedings of the National Academy of Sciences ·Simon Message, Vasile Laza‐Stanca, Patrick Mallia, Hayley L. Parker, Jie Zhu, Tatiana Kebadze, Marco Contoli, G Sanderson, Onn Min Kon, Alberto Papi, Peter K. Jeffery, L Stanciu, Sebastian L. Johnston	373
20	Pathophysiology of viral-induced exacerbations of COPD. 2007 ·PubMed ·A Potena, Gaetano Caramori, Paolo Casolari, Marco Contoli, Sebastian L. Johnston, Alberto Papi	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact